Perindopril + Potassium

What is happening. ACE inhibitors such as perindopril reduce aldosterone secretion, decreasing renal potassium excretion. Adding supplemental potassium can produce clinically significant hyperkalemia, which may cause muscle weakness, paresthesias, and life-threatening cardiac arrhythmias. Risk is amplified in patients with chronic kidney disease, diabetes, advanced age, or volume depletion.

Mechanism. Perindopril inhibits angiotensin-converting enzyme, lowering angiotensin II and aldosterone, which reduces distal nephron potassium secretion; concurrent potassium intake raises serum potassium toward hyperkalemic levels.

Recommendation. Avoid routine potassium supplementation while taking perindopril unless prescribed and monitored by a clinician. Also avoid potassium-containing salt substitutes. If potassium is medically required, serum potassium and renal function should be checked before starting and periodically thereafter. Report symptoms such as palpitations, severe weakness, or numbness promptly.

What is happening. Potassium supplements or potassium-containing salt substitutes can cause hyperkalemia with Perindopril.

Mechanism. Renin-angiotensin system blockade reduces aldosterone-mediated potassium excretion.

Recommendation. Avoid unsupervised potassium supplementation; check potassium and kidney function after initiation, dose changes, or illness.